Search results for "Fatty Liver"

showing 10 items of 513 documents

Endotrophin, a pro-peptide of Type VI collagen, is a biomarker of survival in cirrhotic patients with hepatocellular carcinoma

2021

Aim: Type VI collagen, is emerging as a signaling collagen originating from different types of fibroblasts. A specific fragment of Type VI collagen, the pro-peptide, is also known as the hormone endotrophin. We hypothesized that this fibroblast hormone would be of particular relevance in cancer types with a high amount of fibrosis activity, namely for outcome in hepatocellular carcinoma (HCC) cirrhotic patients. Patients & methods: Plasma C6M, PRO-C6 and alphafeto-protein (AFP) were assessed in 309 patients with mixed etiologies (hepatitis C, hepatitis B, alcohol and nonalcoholic fatty liver) diagnosed as cirrhotics, cirrhotics with HCC, noncirrhotics and healthy controls. Progression-f…

collagen0301 basic medicinemedicine.medical_specialtyHepatocellular carcinomaextracellular matrixGastroenterology03 medical and health sciences0302 clinical medicineSDG 3 - Good Health and Well-beingFibrosisInternal medicinemedicineneoplasmsHepatologyEndotrophinbusiness.industryHazard ratioFatty liverbiomarkersCancerhepatocellular carcinomaHepatitis CExtracellular matrixHepatitis Bmedicine.diseasedigestive system diseases030104 developmental biologyOncologyHepatocellular carcinomaendotrophinBiomarker (medicine)/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being030211 gastroenterology & hepatologyCollagenbusinessBiomarkersResearch Article
researchProduct

Aknu steatozes riska faktoru un fēču mikrobioma saistības izvērtējums pacientiem ar neinsulīnatkarīgu cukura diabētu

2018

Aktualitāte.Aptuveni divām trešdaļām 2TDM pacientu ir NTAS. 2TDM ir riska faktors tam, lai NTAS attīstītos par steatohepatītu, aknu fibrozi un cirozi. NTAS progresija ir biežāka pacientiem ar augstāku ĶMI, VA un TG līmeni. Ir noteikts, ka šajā pacientu grupā daži zarnu mikrobiāta metagenomiskie modeļi var kalpot par aknu iekaisuma radītājiem. Uzlabotas mikrobiomu analīzes metodes un dziļāka izpratne par sakarībām starp disbiozi un tās ietekmi uz kuņģa-aknu asi var uzlabot NTAS diagnostiku un ārstēšanu. Mērķi.Analizēt sakarību starp fēču mikrobiomu un ALAT līmeni, triglicerīdu līmeni, ĶMI un VA 2TDM pacientiem. Materiāli un metodes.Dati tika iegūti retrospektīvi par 2TDM pacientiem, kuriem t…

diabetes mellitusALATnon-alcoholic fatty liver diseasefaecal microbiotaMedicīna
researchProduct

2021

BACKGROUND Studies investigating a potential association between hypothyroidism and non-alcoholic fatty liver disease (NAFLD) showed conflicting results and large-scale population-based data from Germany on this topic are currently missing. OBJECTIVE It was the aim of this analysis to investigate the impact of thyroid gland disorders on the prevalence of NAFLD in Germany. METHODS In this case-control study, using the German disease Analyzer database (IQVIA), NAFLD patients were matched to patients without NAFLD by age, sex, index year, treating physician, diabetes mellitus type II, and obesity. The main outcome of the study was an association between thyroid gland disorders (hypothyroidism,…

education.field_of_studymedicine.medical_specialtyendocrine system diseasesbusiness.industryPopulationFatty liverThyroidGastroenterologynutritional and metabolic diseasesThyroid Gland Disordermedicine.diseaseLower riskGastroenterologydigestive system diseasesAutoimmune thyroiditisLiver diseasemedicine.anatomical_structureOncologyInternal medicinemedicineRisk factorbusinesseducationUnited European Gastroenterology Journal
researchProduct

Characterization of hypoechoic focal hepatic lesions in patients with fatty liver: diagnostic performance and confidence of contrast-enhanced ultraso…

2007

fatty liverfocal hepatic lesionscontrast-enhanced ultrasound
researchProduct

Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease.

2022

Background & Aims: Obesity-associated inflammation is a key player in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). However, the role of macrophage scavenger receptor 1 (MSR1, CD204) remains incompletely understood. Methods: A total of 170 NAFLD liver biopsies were processed for transcriptomic analysis and correlated with clinicopathological features. Msr1(-/-) and wild-type mice were subjected to a 16-week high-fat and high-cholesterol diet. Mice and ex vivo human liver slices were treated with a monoclonal antibody against MSR1. Genetic susceptibility was assessed using genome-wide association study data from 1,483 patients with NAFLD and 430,101 participants of the U…

immunometabolism610 Medicine & healthGastroenterology and HepatologyInbred C57BLDiet High-FatAntibodiesSTEATOHEPATITIS03 medical and health sciencesMice0302 clinical medicineNon-alcoholic Fatty Liver DiseaseMonoclonalGastroenterologiAnimalsHumansObesity610 Medicine & health030304 developmental biologyInflammation0303 health sciencesScience & Technologyimmunometabolism; inflammation; macrophages; NASH; Animals; Antibodies Monoclonal; Diet High-Fat; Genome-Wide Association Study; Humans; Inflammation; Lipids; Liver; Mice; Mice Inbred C57BL; Obesity; Non-alcoholic Fatty Liver DiseaseGastroenterology & HepatologyHepatologyNASHNASH immunometabolism inflammation macrophagesAntibodies MonoclonalLipids3. Good healthmacrophagesDietALPHAMice Inbred C57BLHigh-Fatmacrophages; immunometabolism; NASH; inflammationLiverinflammation3121 General medicine internal medicine and other clinical medicine030211 gastroenterology & hepatologyHuman medicineLife Sciences & BiomedicineGenome-Wide Association StudyJournal of hepatology
researchProduct

Coffee Restores Expression of lncRNAs Involved in Steatosis and Fibrosis in a Mouse Model of NAFLD

2021

Background and aim: Coffee intake exerts protective effects against non-alcoholic fatty liver disease (NAFLD), although without fully cleared mechanisms. In this study we aimed to assess whether coffee consumption may influence the expression of long non-coding RNAs (lncRNAs) in the liver. Methods: C57BL/6J mice were fed a 12-week standard diet (SD), high-fat diet (HFD) or HFD plus decaffeinated coffee solution (HFD + coffee). Expression of specific lncRNAs involved in NAFLD was analyzed by real-time PCR. For the most differentially expressed lncRNAs, the analysis was also extended to their mRNA targets. Results: Decaffeinated coffee intake reduced body weight gain, prevented NAFLD, lowered…

lncRNA.Liver CirrhosisMalemedicine.medical_specialtyGm16551; H19; NAFLD; coffee; lncRNA; Animals; Coffee; Disease Models Animal; Fatty Liver; Gene Expression; Liver; Liver Cirrhosis; Male; Mice; Mice Inbred C57BL; Non-alcoholic Fatty Liver Disease; RNA Long NoncodingCoenzyme ACircadian clockcoffeeGene ExpressionBiologyInbred C57BLArticlechemistry.chemical_compoundMicelncRNADownregulation and upregulationFibrosisSettore BIO/13 - Biologia ApplicataNon-alcoholic Fatty Liver DiseaseInternal medicineNAFLDmedicineAnimalsTX341-641Messenger RNANutrition and DieteticsH19Nutrition. Foods and food supplyAnimalGm16551Fatty liverNAFLD; coffee; lncRNA; Gm16551; H19nutritional and metabolic diseasesmedicine.diseaseMice Inbred C57BLFatty LiverDisease Models AnimalEndocrinologychemistryLiverLipogenesisDisease ModelsRNARNA Long NoncodingLong NoncodingSteatosisFood Science
researchProduct

2019

Background: Physical inactivity is a major risk factor for nonalcoholic fatty liver disease (NAFLD). Exercise-based prevention interventions for improving cardiorespiratory fitness are a recommended complementary treatment for NAFLD. Achievement of minimally effective physical activity to improve cardiorespiratory fitness among patients typically involves high personal and financial expenses in face-to-face settings. We designed an eHealth approach for patients with NAFLD to improve the cardiorespiratory fitness and report the first results of the HELP (Hepatic Inflammation and Physical Performance in Patients With NASH [nonalcoholic steatohepatitis]) study. Objective: We aimed to assess th…

medicine.medical_specialty020205 medical informaticsbusiness.industryFatty liverPsychological interventionVO2 maxHealth InformaticsCardiorespiratory fitness02 engineering and technologymedicine.diseaseEndurance trainingNonalcoholic fatty liver disease0202 electrical engineering electronic engineering information engineeringmedicinePhysical therapyRisk factorAdverse effectbusinessJournal of Medical Internet Research
researchProduct

Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease.

2019

Background & Aim There is an unmet need for non-invasive biomarkers in non-alcoholic fatty liver disease (NAFLD) that can diagnose advanced disease and identify patients suitable for clinical trials. The PRO-C3 collagen neo-epitope is a putative direct marker of fibrogenesis. We assessed the performance of PRO-C3 in a large, well-characterised international NAFLD cohort and report the development and validation of 2 novel panels for the diagnosis of advanced fibrosis (F≥3) in NAFLD, including a simplified clinical score which eliminates the need for online calculators. Methods Plasma PRO-C3 levels were determined in a prospectively recruited international cohort of 449 patients with biopsy …

medicine.medical_specialtyADVANCED FIBROSISSCORING SYSTEMPROGRESSIONGastroenterologySTEATOHEPATITIS03 medical and health sciences0302 clinical medicineFibrosisInternal medicineNAFLDBiopsyInternal MedicineImmunology and AllergyMedicineSTEATOSISPRO-C3Stage (cooking)lcsh:RC799-869030304 developmental biologySteatohepatitisRISK0303 health sciencesScience & TechnologyHepatologymedicine.diagnostic_testGastroenterology & Hepatologybusiness.industryFatty liverfibrosisGastroenterologyNASHDIABETES-MELLITUSCHRONIC HEPATITISBiomarkermedicine.disease3. Good healthClinical trialCohortBIOPSYBiomarker (medicine)030211 gastroenterology & hepatologylcsh:Diseases of the digestive system. GastroenterologySteatohepatitisbusinessLife Sciences & BiomedicineResearch ArticleJHEP reports : innovation in hepatology
researchProduct

Evaluation of the Possible Contribution of Antioxidants Administration in Metabolic Syndrome

2011

The metabolic syndrome (MetS) is common, and its associated risk burdens of diabetes and cardiovascular disease (CVD) are a major public health problem. The hypothesis that main constituent parameters of the MetS share common pathophysiologic mechanisms provides a conceptual framework for the future research. Exercise and weight loss can prevent insulin resistance and reduce the risk of diseases associated with the MetS. Interrupting intracellular and extracellular reactive oxygen species (ROS) overproduction could also contribute to normalizing the activation of metabolic pathways leading to the onset of diabetes, endothelial dysfunction, and cardiovascular (CV) complications. On the other…

medicine.medical_specialtyAntioxidantmedicine.medical_treatmentHyperlipidemiasDiseaseBioinformaticsmetabolic syndromeAntioxidants03 medical and health sciences0302 clinical medicineInsulin resistancecardiovascular diseaseWeight lossinsulin resistanceDiabetes mellitusInternal medicineDrug Discoverymedicineoxidative stressHumansObesityEndothelial dysfunctionantioxidants cardiovascular disease insulin resistance metabolic syndrome oxidative stress reactive oxygen species.Dyslipidemias030304 developmental biologyreactive oxygen speciesInflammationMetabolic SyndromePharmacology0303 health sciencesbusiness.industryThrombosismedicine.disease3. Good healthFatty LiverClinical trialOxidative StressantioxidantsEndocrinologyObesity Abdominal030220 oncology & carcinogenesisHypertensionInsulin ResistanceMetabolic syndromemedicine.symptombusinessSignal TransductionCurrent Pharmaceutical Design
researchProduct

Role of the gastroenterologist in the management of the obese patient.

2017

Obesity is a highly prevalent disease worldwide, and one in which gastroenterologists can play an important role. Some digestive diseases are more common in obese patients, and preoperative evaluation may be required in some cases. Additionally, bariatric surgery can lead to digestive complications in the short and long term that require intervention, and endoscopic treatment can be an important factor in weight loss. The aim of this review is to highlight the role of the gastroenterologist in the management of obese patients who are either scheduled for or have undergone surgical or endoscopic treatment for obesity.

medicine.medical_specialtyBariatric SurgeryDiseaseGallstonesGastroenterologyPostgastrectomy SyndromesHelicobacter Infections03 medical and health sciences0302 clinical medicinePostoperative ComplicationsWeight lossNon-alcoholic Fatty Liver DiseaseIntervention (counseling)Internal medicinemedicineHumansEndoscopy Digestive SystemObesityStomach UlcerPhysician's RoleHelicobacter pyloribusiness.industryfungiGastroenterologyfood and beveragesDisease Managementmedicine.diseaseObesityObesity Morbid030220 oncology & carcinogenesisGastroesophageal Reflux030211 gastroenterology & hepatologyDisease Susceptibilitymedicine.symptombusinessColorectal NeoplasmsGastrointestinal HemorrhageEndoscopic treatmentGastroenterologia y hepatologia
researchProduct